Mode of administration | Indication for IGRT | |||
---|---|---|---|---|
Infusion pump | Manual | PID | SID | |
Patient characteristics at baseline | n = 71 | n = 54 | n = 61a | n = 64b |
Age, median (range) | 66 (28–83) | 63 (19–82) | 57 (19–79) | 69 (48–83) |
Sex, n (%) | ||||
Female | 44 (62.0) | 39 (72.2) | 47 (77.0) | 36 (56.3) |
Male | 27 (38.0) | 15 (27.8) | 14 (23.0) | 28 (43.8) |
Mode of administration, n (%) | ||||
Infusion pump | 71 (100) | 0 | 33 (54.1) | 38 (59.4) |
Manual | 0 | 54 (100) | 28 (45.9) | 26 (40.6) |
Indication for IGRT, n (%) | ||||
PIDa | 33 (46.5) | 28 (51.9) | 61 (100) | 0 |
SIDb | 38 (53.5) | 26 (48.1) | 0 | 64 (100) |
Infusion and dosing parameters at 12 monthsc | n = 65 | n = 42d | n = 52 | n = 55 |
Infusion volume/infusion, median (IQR), ml | 43 (40–60) | 30 (20–40) | 40 (25–50) | 40 (35–50) |
Infusion duration, median (IQR), minutes | 60 (45–73) | 24 (10–40) | 43 (20–65) | 60 (40–65) |
Number of infusion sites/infusion, median (IQR) | 2 (2–3) | 2 (1–2) | 2 (2–4) | 2 (2–3) |
1 site, n (%) | 1 (1.7) | 9 (33.3) | 8 (18.6) | 2 (4.5) |
2 sites, n (%) | 32 (53.3) | 17 (63.0) | 21 (48.8) | 28 (63.6) |
3 sites, n (%) | 16 (26.7) | 0 | 3 (7.0) | 13 (29.5) |
> 3 sites, n (%) | 11 (18.3) | 1 (3.7) | 11 (25.6) | 1 (2.3) |
Number of infusions/month/patient, median (IQR) | 4 (4–4) | 4 (4–8) | 4 (4–8) | 4 (4–4) |
Maximal infusion rate/site, median (IQR), (ml/h)e | 40.0 (34.0–59.0) | – | 33.5 (25.7–40.0) | 40.0 (35.0–60.0) |
Weekly dose, median (IQR), g | 8.0 (6.0–10.0) | 8.0 (6.0–8.0) | 9.0 (7.0–12.0) | 8.0 (6.0–10.0) |
Dosing interval, n (%) | ||||
Daily | 0 | 0 | 0 | 0 |
2–6 times/week | 2 (3.1) | 17 (40.5) | 15 (28.8) | 4 (7.4) |
Once weekly | 56 (87.5) | 25 (59.5) | 34 (65.4) | 47 (87.0) |
Every 2 weeks | 4 (6.3) | – | 2 (3.8) | 2 (3.7) |
Other | 2 (3.1) | – | 1 (1.9) | 1 (1.9) |
IgG trough levels, g/l | ||||
Median (IQR) | 8.6 (7.9–10.6) | 9.1 (8.3–11.0) | 9.9 (8.6–11.8) | 8.3 (7.9–9.0) |
Range | 3.6–14.5 | 5.6–13.4 | 3.6–13.4 | 5.6–14.5 |